Sonnet BioTherapeutics Announces Regulatory Approval For Initiation Of Clinical Trial Of SON-1010 Combined With Atezolizumab In Australia
Portfolio Pulse from Benzinga Newsdesk
Sonnet BioTherapeutics has received regulatory approval to initiate a clinical trial of SON-1010 combined with atezolizumab in Australia.
June 20, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sonnet BioTherapeutics' stock may see a positive impact as the company receives regulatory approval for a clinical trial of SON-1010 combined with atezolizumab in Australia.
The regulatory approval for the initiation of the clinical trial is a significant milestone for Sonnet BioTherapeutics. This news may lead to increased investor confidence and a potential positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100